CRXT - Cantor lists pharma stocks with notable changes in short interest

Referring to the most up-to-date market data as of Apr. 11, Cantor Fitzgerald has listed the biotech companies with the most notable changes in the short interest. The nano-cap commercial-stage pharma company, Clarus Therapeutics (CRXT) dominates the list with over ten times increase in short interest. It is followed by United Therapeutics with a rise of ~67%, while the shares of the animal health company, Zoetis (ZTS) indicated a 10% spike. Additionally, the analyst Louise Chen pointed out that clinical-stage biotechs, Aravive (ARAV) and PolyPid (PYPD) led the stocks with the most meaningful declines as their short interest fell ~83% and ~51%, respectively. Generic drugmaker Viatris (NASDAQ:VTRS) also showed a meaningful drop in short interest with a decline of ~21%. Meanwhile, the commercial-stage companies, Heron Therapeutics (HRTX) and Omeros Corporation (OMER) led the stocks with the highest short floats with ~40% and ~19% of shorted shares in the market compared

For further details see:

Cantor lists pharma stocks with notable changes in short interest